Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective

Price Jennifer C.; Terrault Norah A.

首页> 外文期刊>Liver international : >Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective

【24h】

Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective

机译：在等待入组的丙型肝炎患者中应选择使用Sofosbuvir和Ribavirin

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Liver international :》 |2015年第1期|共2页
作者
Price Jennifer C.; Terrault Norah A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内科学;
关键词

相似文献

外文文献
中文文献
专利

1. Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective [J] . Price Jennifer C., Terrault Norah A. Liver international : . 2015,第1期

机译：在等待入组的丙型肝炎患者中应选择使用Sofosbuvir和Ribavirin
2. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C [J] . Satsangi Sandeep, Mehta Manu, Duseja Ajay, Journal of gastroenterology and hepatology . 2017,第4期

机译：用Sofosbuvir Plus利巴韦林的双重治疗与Pegylated干扰素加上Sofosbuvir Plus利巴韦林的三重疗法有效3患者慢性丙型肝炎患者
3. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir [J] . Modi A. A., Nazario H. E., Gonzales G. R., Alimentary pharmacology & therapeutics. . 2018,第10期

机译：Ledipasvir / sofosbuvir的安全性和有效性与丙基肝炎基因型中的利巴韦林1患者1名患者，包括与Simeprevir / Sofosbuvir先前治疗的失败肝硬化
4. HLA-C gene in Hepatitis C Virus infected Patients in Egypt, to estimate the relation between HLA-C gene and Interferon/Ribavirin as treatment for hepatitis C virus [C] . SHADEN MUAWIA HANAFY, AMAL AHMED ABBAS, SAFY KABEEL ALY MANSOUR International Conference on Cellular and Molecular Biology, Biophysics and Bioengineering . 2015

机译：HLA-C基因在丙型肝炎病毒中感染埃及患者，估计HLA-C基因和干扰素/利巴韦林与丙型肝炎病毒治疗的关系
5. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010

机译：利巴韦林在慢性丙型肝炎基因型1感染患者中的群体药代动力学和功效。
6. Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus [O] . Phil McEwan, Samantha Webster, Thomas Ward, 2017

机译：估计达卡他韦+索非布韦+索非布韦+雷巴韦林对基因3型丙型肝炎病毒患者的成本效益
7. Efficacy and Safety of Peg-Interferon/Sofosbuvir/Ribavirin VS Sofosbuvir/Simeprevir in Egyptian chronic hepatitis C patients [O] . Mohamed Fathallah, Mohammed Elhamouly, Amany Moustafa, 2018

机译：埃及慢性乙型肝炎患者的PEG-Interferon / Sofosbuvir /利巴韦林与Simeprevir的疗效和安全性

Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective

著录项

引文网络

相似文献

相关主题

期刊订阅